cyrilzakka/clinical-trials huggingface dataset:
Retrospective Analysis of the Clinical Characteristics of Retinal Vein Occlusion

To explore the clinical characteristics of patients with RVO, and to analyze the relationship between RVO and various underlying diseases, ocular conditions, lifestyle, imaging findings and treatment response. To systematically analyze the clinical data of patients with different types of RVO, further reveal the potential mechanism of its occurrence and development, and evaluate the efficacy and safety of different treatment methods, in order to provide more scientific basis for clinical treatment.

To explore the clinical characteristics of patients with RVO, and to analyze the relationship between RVO and various underlying diseases, ocular conditions, lifestyle, imaging findings and treatment response. To systematically analyze the clinical data of patients with different types of RVO, further reveal the potential mechanism of its occurrence and development, and evaluate the efficacy and safety of different treatment methods, in order to provide more scientific basis for clinical treatment.

Patients discharged from our hospital from January 2018 to December 2024 with the diagnosis of retinal vein occlusion were retrospectively investigated. The medical history of each patient was reviewed, and the basic information, past medical history, eye examinations and their results, treatment plans, and prognosis information of the patients were recorded in detail.

Eligibility Criteria:
Inclusion Criteria:

* meeting the diagnostic criteria for RVO (including BRVO and CRVO)

Exclusion Criteria:

* patients with other ocular diseases other than RVO, such as iridocyclitis, age-related macular degeneration, central serous chorioretinopathy and optic neuropathy;
* patients with systemic inflammatory diseases and other systemic diseases other than diabetes, hypertension, coronary heart disease and cerebral infarction that may affect blood indexes;
* patients with incomplete clinical data and information.
Assessment of Two Point Discrimination

When the studies in the literature are examined, no study has been reached to examine whether median nerve mobilization causes changes in two-point discriminatory values in healthy individuals. This study aimed to investigate the effect of median nerve mobilization exercise on two-point discrimination in healthy adult male and female participants. Secondly, it was aimed to determine the role of variables such as gender, age, BMI (weight in kilograms, height in meters and weight and height will be combined to report BMI in kg/m\^2), smoking, dominant extremity and physical activity level in 2-point discrimination.

Two-point discrimination is one of the most important cortical senses that require strong tactile sensitivity and the ability to distinguish two points from one point on the skin. Neural mobilization has been reported to be effective in the nerve-related waist, leg, neck, arm, and plantar heel pain, but there is still insufficient evidence for other neuromusculoskeletal problems. It has been stated that factors such as application technique, type and patient characteristics of mobilization are effective in the treatment and more comprehensive studies should be done on this subject. This study aimed to investigate the effect of median nerve mobilization exercise on two-point discrimination in healthy adult male and female participants.

120 healthy female and male adult individuals (60 females, 60 males) will be included in the study. Individuals will be divided into two groups as female and male (n = 60), and a two-point discrimination test will be performed on the palmar face of both hands from the distal phalanx, forefinger, middle finger and palm. After the evaluation, the participants in both groups were randomly divided into two groups as the exercise group (n = 30) and control group (n = 30). Participants in the exercise group will perform 2 sets of 5 repetitive Median nerve mobilization exercises (total of 20 sessions) per day for 10 days. After the exercise program, the two-point discrimination measures will be repeated in all groups.

Eligibility Criteria:
Inclusion Criteria:

* Healthy Volunteers
* Adapt to median nerve mobilization exercise

Exclusion Criteria:

* Upper extremity neuromuscular disease
* The presence of neurological disease
* Skin diseases (burn or scar tissue in upper extremity)
* Diabetes mellitus
A Research on Hidden Blood Loss in Open Radical Hysterectomy and Pelvic Lymphadenectomy

The aim of this cross-sectional study is to evaluate the hidden blood loss in patients who underwent open radical hysterectomy and identity its risk factors.

The electronic medical data of 100 patients who undergo open radial hysterectomy in the following year to treat cervical cancer will be analyzed retrospectively in this study. The amount of hidden blood loss will be calculated according to Gross's formula. And multiple linear regression analysis will be employed to identify its risk factors.

Eligibility Criteria:
Inclusion Criteria:

1. Volunteer to participate in the study with informed consent;
2. Females aged 20-80 who are confirmed with cervical cancer and are treated with open radical hysterectomy and pelvic lymphadenectomy.

Exclusion Criteria:

1. Pregnancy, lactation, postmenopause, or planned pregnancy within two years;
2. Suspected or identified as other tumors of genital tract;
3. History of hyperparathyroidism, infectious diseases (tuberculosis, AIDS), autoimmune diseases, or digestive system diseases (malabsorption, crohn disease and dysentery);
4. Other diseases or heavy injuries that will interfere with the results;
5. Simultaneous participation in another clinical study with investigational medicinal product(s) or researcher thinks the subjects are not suitable for this trial.
Use of Two Dissolvable Therapeutics Under Removable Partial Dentures

Older removable denture wearing adults suffer from a complex set of oral health challenges, with relatively few solutions identified at this time. This is substantiated by statistics concerning the geriatric population on the correlation of poor oral health and the degradation of an individual's overall quality of life. The most recent National Health and Nutrition Examination Survey data found that 1 in 8 U.S. adults over the age of 65 are completely edentulous. A shift from complete edentulism to partial edentulism was also seen in this survey data, as the average individual over 65 had only 21 teeth remaining. Thus, partial edentulism remains a significant burden on seniors as well.

Clearly, there exists both a great need and desire for improved implementation of proven oral-health strategies among this population, as well as the development of new preventive interventions and minimally invasive treatment strategies beyond traditional denture adhesive products.

This proposed clinical trial intends to investigate two such potential treatment aids. In follow-up from our recent pilot study investigating MI Paste's application on the intaglio of complete dentures, in which our current findings have shown that the use of MI Paste can predictably increase the buffering capacity of a patient's saliva, our current proposal targets to further increase the study's sample size to improve the statistical power regarding subjective patient reports.

The primary aims of this proposed study are to collect further data on how MI Paste affects patients' subjective evaluations of the comfort and retention of their denture, as well as dry mouth symptoms in patients reporting xerostomia.

Furthermore, this study will include a second therapeutic intervention, Biotene Dry Mouth Gel (OTC), which will provide an additional contrast variable involving patient preferences regarding therapeutics under their removable prostheses. We hypothesize that the use of both therapeutics underneath removable dentures will provide added retention and stability to the prosthesis on patient reports, further coinciding with improved evaluations of comfort and function. Additionally, we hypothesize that the subjective improvements in patients self-reporting xerostomia will be of a statistically greater magnitude than those noticed by patients with normal salivary function, as xerostomia has been associated with increased denture discomfort in past literature.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-99
* Patients with a removable prosthesis (e.g., partial denture, complete denture)
* Removable prosthesis must have been made at the University of Iowa College of Dentistry's Department of Family Dentistry clinic within the past 10 years.

Exclusion Criteria:

* Casein (i.e., protein found in milk or other dairy products) allergy
* Lactose intolerance
* Multiple food or cosmetic ingredient allergies in their health history
* Ill-fitting dentures that need to be remade or relined
Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours

The purpose of this study is to investigate the taste preference in children of 3 different flavours of the ESL oral suspension.

Children between the age of 5 and \<8 years who are patients of the participating investigators will be screened for participation in the study. This may be at a regularly planned visit or the investigators may invite children who would be suitable candidates. Children who agree to participate will be invited to come back to the clinic on a single Study Day and will be randomised to a particular sequence of flavours. On the Study Day, all children will be given 3 different flavoured samples of Eslicarbazepine acetate (ESL) oral suspension for tasting, in the sequence to which they were randomised, in a double-blind, standardized setting. Each sample will consist of 2.5 mL and is to be given with a spoon in a double-blind manner, and is not to be swallowed. After tasting and spitting out each sample the child will be asked to rate the taste on a 10 cm visual analogue scale incorporating a facial hedonic scale. At the end of the session, the child will also be asked which flavour they thought tasted the best and which tasted the worst, to assess overall taste. A follow-up telephone contact interview will be performed between 1 and 4 days after the Study Day to collect adverse event (AE) data.

Eligibility Criteria:
Inclusion Criteria:

* A written informed consent form signed by the subject's parent(s) or guardian(s) and an assent form for any 7-year-old subjects signed by subjects.
* Male or female, between the age of 5 to \<8 years.
* Diagnosed with partial-onset epilepsy.
* Is considered, in the opinion of the investigator, to be able to make the required taste assessment.

Exclusion Criteria:

* Uncontrolled cardiac, renal, hepatic, endocrine, gastrointestinal, metabolic, haematological, or oncology disorder.
* Known hypersensitivity to carboxamide derivatives or tricyclic antidepressants.
* Strong congestion, flu, or any other acute illness that could influence the child's sense of taste.
* A known swallowing or taste perception problem.
* Currently or previously treated with ESL.
* Concomitant participation in another drug clinical trial.
* Any other condition or circumstance that, in the opinion of the investigator, could compromise the subject's ability to comply with the study protocol.
Investigating the Inotropic Potential of Apelin

The apelin-APJ system is a recently discover hormone system that has several important actions in the cardiovascular system. Apelin causes the heart pump with more force and also causes blood vessels to relax. Studies to date show that people with reduced pumping function of the heart have lower levels of apelin in the bloodstream compared to people with normal heart function. We have previously given apelin to healthy volunteers and people with reduced pumping function and this increases the heart's contraction. However, this has only been assessed over a short time period, around fifteen minutes, and we now want to know if this effect is seen over a longer period.


Eligibility Criteria:
Inclusion Criteria:

Healthy volunteers:

\>18yrs

Heart failure patients;

* New York Heart Failure class II-IV
* Ejection fractional \<35% or fractional shortening \<20% within previous 6months.

Exclusion Criteria:

All subjects,

* Females of child bearing age not on adequate contraception
* Lack of informed consent
* Age \<18yrs
* Current involvement in any other research study
* Systolic BP \>190 or \<100
* Malignant arrhythmias
* Renal or hepatic failure
* Haemodynamically significant aortic stenosis
* Severe or significant co-morbidity
* Pacemakers

Healthy volunteers

* Any regular medication
* Previous history of any cardiovascular disease
Leipzig Childhood Obesity Study

The aim of this study is to identify polymorphisms that make children and adolescents more prone to obesity and metabolic dysfunction, as well as to identify biomarkers that are linked to causes and consequences of obesity.

In order to identify single nucleotide polymorphisms blood and serum samples during oral glucose tolerance testing are routinely obtained from pediatric patients visiting the adiposity outpatient clinic.

Eligibility Criteria:
Inclusion Criteria:

* all pediatric patients seen in the adiposity outpatient clinic
* informed patient consent

Exclusion Criteria:

* none
NIR Fluorescent Molecular Probe for the Identification of Breast Tissue

Accurate evaluation of tumor boundaries in breast-conserving surgery is critical to reducing the second operation of patients. Near-infrared (NIR) fluorescence imaging using molecular agents has shown promise for in situ imaging during resection. However, very effective probes can be applied to clinical trials up to now, which limits the clinical application of fluorescence imaging. Here we developed a new technology that can quickly identify the tumor area of the resected breast tissue during the operation and distinguish the tumor boundary. In brief, the breast tissues were incubated with the probe immediately after intraoperative resection and imaged to identify the tumor area and distinguish the tumor boundary. The accuracy of fluorescence imaging was confirmed by pathological diagnosis.

After enrollment, the patients received surgical treatment according to clinical diagnosis and treatment. During the operation, the excised breast tissue was incubated, and the specific procedure was as follows.

1. Preparation of the incubation solution: The probe was dissolved in phosphate buffer saline(PBS) buffer as the incubation solution at room temperature in the dark.
2. In vitro incubation of fresh breast cancer tissues: The fresh excision breast cancer tissues were completely soaked in the incubation solution for about 10 minutes, followed by 5 minutes rinse with PBS buffer and drying with the use of absorbent paper.
3. Analysis of the images in the "Digital Precision Medicine(DPM)" NIR-II system. The DPM parameter was set up before scaling. Then fluorescence imaging was performed with the DPM NIR-II system. And the result was analyzed to identify the tumor area and distinguish the tumor boundary.
4. Confirmed the diagnosis by pathological examination.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients over 18 years of age; Female; Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment; Good operative candidate; Subject capable of giving informed consent and participating in the process of consent.

Exclusion Criteria:

* Patients unable to participate in the consent process; Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc; Other conditions that the researcher considers inappropriate to participate in the study.
Evaluating Medium-chain Triglycerides as a Temporary Intraocular Tamponading Agent for Retinal Detachment

Background : Surgery is needed in order to flatten and position a detached retina onto the choroid, to allow sealing of the tears and to prevent or reverse vision loss. In case of complex retinal detachment vitrectomies followed by ocular endotamponade - non-solid implants used in ophthalmology - is the most common treatment. Despite several options used by surgeons were not entirely satisfactory, no innovation were marketed in the ocular endotamponade field since decades.

Purpose : Regarding comparative physico-chemical properties of medium-chain triglycerides (MCT) with current tamponading agents (silicone oil or gases), it will be proposed to evaluate the MCT as an ocular endotamponade product.

Previously a nonclinical study has provide an assessment of the safety and the local tissue effects of the Medium-Chain Triglyceride (MCT) tamponade agent manufactured by the company Arcadophta : There were no histopathologic findings or irritation events that were directly attributable to the MCT device. In conclusion, under the conditions of the study, the MCT device did not induce any adverse local tissue effects compared to a control tamponading agent silicone oil.

The present clinical study is the first use of MCT tamponade agent which assigns human participants. The MCT tamponade agent studied is manufactured by the company Arcadophta and designed as a Class IIb medical device in Europe.

Tamponment efficacy and human eye safety of the device are supported by a flatten retina observation and a healthy eye fundus exam respectively as long as the tamponade agent is present.

The patient treatment is the classical surgical procedure which is used for retinal detachment with silicone oil.

* Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.
* MCT ablation after 4 to 6 weeks (after effective retinopexy) The patient follow-up begins 4 days before treatment , then 3 time-points exams are performed before MCT ablation and 4 time-points exams are performed after MCT ablation for a total patient follow-up duration of 6 months.

Eligibility Criteria:
Inclusion Criteria:

* Each patient with retinal detachment which requires a classical surgical procedure with silicone oil.
* Proliferative vitreoretinopathy over C2 regarding Retina Society classification
* Retinal detachment due to trauma to the eye
* Retinal detachment due to equatorial wound dehiscence which requires a classical surgical procedure with silicone oil.
* Retinal detachment due to complex proliferative diabetic retinopathy
* Recurrence of retinal detachment after ophthalmic gaz treatment
* Retinal detachment due to giant tear (\>90°C independently of the location into the eye.

Exclusion Criteria:

* monophthalmic patient
* Eye with corneal dystrophy
* Intraocular pressure \> 25 mmHg under treatment
* Patient with travel difficulty or living place far away from the clinic
* Patient participating to another clinical study.
* Pregnant women or breastfeeding women
* Patient under tutors or curators
An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines

This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.

Objectives Within-group changes in outcomes will be compared from baseline to the end of the study period.

Primary Outcome Measures:

Biomarkers in blood, measured using the Olink Target 48 Cytokine panel:

Tumor Necrosis Factor (TNF) Interleukin-1 Beta (IL1B) Interleukin-8 (CXCL8) Vascular Endothelial Growth Factor A (VEGFA)

Secondary Outcome Measures:

Remaining biomarkers in the Olink Target 48 Cytokine panel 36-Item Short Form Health Survey (SF-36) Frailty Index for Elders (FIFE) Depression Anxiety Stress Scale-21 (DASS-21)

Side effect profile including:

Number, type, severity, causality, and outcome of adverse events or unanticipated problems

Symptoms of aging, assessed by:

Aging Male Symptom scale Aging Female Symptom scale

Participant Details:

Study Duration per Participant: 7 days Total Number of Participants: 40

Eligibility Criteria:
Inclusion Criteria:

* Provide voluntary, written, informed consent to participate in the study
* Agree to provide a valid cell phone number and are willing to receive communications through text.
* Healthy adults 45 - 79 years of age Can read and write English
* Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly.
* Willing to self-administer the fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives NHC access to the results of these tests.
* Willing to complete questionnaires, records, and diaries associated with the study.

Exclusion Criteria:

* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
* Known food intolerances/allergy to any ingredients in the product
* Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer
* Having had a significant cardiovascular event in the past 6 months
* Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
* On immunosuppressive therapy
* Individuals who were deemed incompatible with the test protocol
* Adults lacking capacity to consent
Real-time Monitoring of Motor Cortical Activity Induced by Low-frequency Repetitive Transcranial Magnetic Stimulation

In this study, we investigated the effect of low-frequency repetitive trans cranial magnetic stimulation, one of the noninvasive brain stimuli, on the functional changes of the bilateral motor cortical activity in normal subjects using functional near infrared spectroscopy (fNIRS).

In normal subjects,

1. the effect of low-frequency repetitive transcranial magnetic stimulation on cerebral cortex are measured in real time using fNIRS.
2. Changes in cerebral cortical activity before and after stimulation are measured using the motor function test and the motor-induced potential test

Eligibility Criteria:
Inclusion Criteria:

* Healthy adult men and women without history of central nervous system disease and abnormalities

Exclusion Criteria:

* Under 18 years old, 70 years old or older
* A person who has inserted a metal object in a skull
* A person with complete occlusion of the carotid artery
* A person with epilepsy
* Pregnant and lactating women
* Who is not eligible for the test
Observation of Treatment Patterns With Lucentis in Approved Indications

A multicentre, open-label, non-interventional study to observe treatment patterns in patients with wet age-related macular degeneration (wAMD), with visual impairment due to diabetic macular edema (DME), due to macular edema following retinal vein occlusion (RVO) or due to chorioidal neovascularization following pathologic myopia (mCNV) with repeated intravitreal injections of Lucentis® (Ranibizumab) including optional OCT monitoring over a 24 months observational period under real life conditions.


Eligibility Criteria:
Inclusion criteria:

* Presence of

  * neovascular (wet) age-related macular degeneration (AMD),
  * visual impairment due to diabetic macular oedema (DME),
  * visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) or
  * visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM)
* Patients for whom a therapy with Lucentis® is medically indicated.
* Written patients informed consent.

Exclusion criteria:

* As described in the SmPC.
* Preceding intravitreal treatment of the study eye with anti-VEGF drugs in the last three months before enrollment
* Preceding intravitreal treatment of the study eye with steroids